Cargando…
Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers
BACKGROUND: Molecular components in blood, such as proteins, are used as biomarkers to detect or predict disease states, guide clinical interventions and aid in the development of therapies. While multiplexing proteomics methods promote discovery of such biomarkers, their translation to clinical use...
Autores principales: | Johansson, Camilla, Hunt, Helian, Signorelli, Mirko, Edfors, Fredrik, Hober, Andreas, Svensson, Anne-Sophie, Tegel, Hanna, Forstström, Björn, Aartsma-Rus, Annemieke, Niks, Erik, Spitali, Pietro, Uhlén, Mathias, Szigyarto, Cristina Al-Khalili |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258980/ https://www.ncbi.nlm.nih.gov/pubmed/37308827 http://dx.doi.org/10.1186/s12014-023-09412-1 |
Ejemplares similares
-
Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy
por: Strandberg, Kristin, et al.
Publicado: (2020) -
Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy
por: Signorelli, Mirko, et al.
Publicado: (2019) -
Circulating Biomarkers for Duchenne Muscular Dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2015) -
Longitudinal metabolomic analysis of plasma enables modeling disease progression in Duchenne muscular dystrophy mouse models
por: Tsonaka, Roula, et al.
Publicado: (2020) -
Biomarkers of Duchenne muscular dystrophy: current findings
por: Szigyarto, Cristina Al-Khalili, et al.
Publicado: (2018)